Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).
Amit Bahl
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Susan Masson
Honoraria - Sanofi
Zafar Malik
No relevant relationships to disclose
Alison J Birtle
Consultant or Advisory Role - Sanofi
Santhanam Sundar
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Robert J Jones
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Nicholas David James
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Malcolm David Mason
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Satish Kumar
No relevant relationships to disclose
David Bottomley
No relevant relationships to disclose
Anna Lydon
Consultant or Advisory Role - Sanofi
Simon Chowdhury
No relevant relationships to disclose
James Wylie
No relevant relationships to disclose
Johann Sebastian De Bono
Honoraria - Sanofi